OSE Immunotherapeutics Enters a Loan Agreement of up to €25 Million with the European Investment...

This loan will further support the progress and expansion of OSE Immunotherapeutics’ lead clinical development programs in diseases with high unmet medical needs,

Divided into three tranches including two tranches of €10 million each and a third tranche of €5 million,

Agreement part of the European Investment Bank’s strategy to support biotech companies developing a high-level of expertise in various areas such as OSE’s immunotherapy programs, including its vaccine program against SARS-CoV-2...